Radioisotopic treatment of bone pain from metastatic prostate cancer |
| |
Authors: | Oliver Sartor |
| |
Institution: | (1) Stanley Scott Cancer Center, Department of Hematology/Oncology, Louisiana State University School of Medicine, Room 459, 533 Bolivar, 70112 New Orleans, LA, USA |
| |
Abstract: | Hormone-refractory prostate cancer patients with painful bony metastatic lesions are potential candidates for boneseeking
radiopharmaceutical therapies. After careful assessment of symptoms and localization of pain, a bone scan is the single most
useful imaging modality for the clinician to assess patients for the presence and distribution of osteoblastic lesions. Increased
uptake (compatible with bony metastases) on a conventional bone scan is currently a prerequisite for treating patients with
a bone-targeted therapeutic isotope. Determining whether metastatic bony involvement is focal or diffuse is also important
in the clinical decision-making process. Patients with multifocal metastatic disease are excellent candidates for systemic
therapies, whereas patients with unifocal metastatic disease may be more appropriate candidates for focal therapies such as
external-beam radiation. Patients who are poorly tolerant of narcotics should be actively considered for alternative treatments
such as systemic radiopharmaceuticals. Contraindications to administration of current boneseeking radioisotopes include substantial
degrees of renal insufficiency or bone marrow suppression. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|